First human test of novel heart failure drug begins

NCT ID NCT06625307

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new medicine called NNC0537-1482, designed to potentially treat heart failure. It is the first time this drug is given to humans, so healthy volunteers receive a single injection under the skin to check for safety and how the body processes it. Participants are randomly assigned to receive either the drug or a placebo. The results will help decide if further testing in heart failure patients is warranted.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

NNC0537-1482

What this could lead to

If safe and effective, this could lead to a new treatment option for people with heart failure.

What could go wrong

This is an early Phase 1 trial in healthy volunteers, so it may not work in heart failure patients or may have unexpected side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • ICON - location Groningen

    Groningen, 9728 NZ, Netherlands